Collin Gage serves as Chief Executive Officer and Director of ARMR Sciences Inc., where he leads the company’s strategic vision, capital formation, and national positioning in preventive biologics. After being personally impacted by addiction and overdose, Collin committed his career to challenging conventional approaches and advancing innovative solutions capable of addressing the evolving synthetic drug crisis. He founded ARMR Sciences with a focused mission: to prevent overdose and addiction.

Prior to founding ARMR Sciences, Collin served as Senior Vice President of Corporate Development and Investor Relations at Definium Therapeutics (NASDAQ: DFTX), a clinical-stage biopharmaceutical company advancing novel therapies for addiction and mental health disorders. In this role, he led firm-wide capital markets strategy and investor relations, helping position the company to raise more than $500 million in public and private financings to support late-stage clinical development. Definium Therapeutics has advanced multiple assets into Phase III clinical trials and received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.

Earlier in his career, Collin led research and investment initiatives at a private family office focused on early-stage, venture-backed companies. In that role, he advised founders and executive teams on complex financial strategy, capital structuring, and navigation of private and public capital markets. Prior to his investment experience, he served as a consultant to Tesla (NASDAQ: TSLA), where he contributed to identifying and executing emerging market growth strategies. He began his career at Point72 Asset Management, a global multi-strategy investment firm.

Collin holds a Bachelor of Science in Economics and Finance from The Ohio State University.